Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 12 2021
30 12 2021
Historique:
received:
17
09
2021
accepted:
13
12
2021
entrez:
31
12
2021
pubmed:
1
1
2022
medline:
19
1
2022
Statut:
epublish
Résumé
It is partially unknown whether the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection persists with time. To address this issue, we detected the presence of SARS-CoV-2 antibodies in different groups of individuals previously diagnosed with COVID-19 disease (group 1 and 2), or potentially exposed to SARS-CoV-2 infection (group 3 and 4), and in a representative group of individuals with limited environmental exposure to the virus due to lockdown restrictions (group 5). The primary outcome was specific anti-SARS-CoV-2 antibodies in the different groups assessed by qualitative and quantitative analysis at baseline, 3 and 6 months follow-up. The seroconversion rate at baseline test was 95% in group 1, 61% in group 2, 40% in group 3, 17% in group 4 and 3% in group 5. Multivariate logistic regression analysis revealed male gender, close COVID-19 contact and presence of COVID-19 related symptoms strongly associated with serological positivity. The percentage of positive individuals as assessed by the qualitative and quantitative tests was superimposable. At the quantitative test, the median level of SARS-CoV-2 antibody levels measured in positive cases retested at 6-months increased significantly from baseline. The study indicates that assessing antibody response to SARS-CoV-2 through qualitative and quantitative testing is a reliable disease surveillance tool.
Identifiants
pubmed: 34969967
doi: 10.1038/s41598-021-04279-4
pii: 10.1038/s41598-021-04279-4
pmc: PMC8718534
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24503Informations de copyright
© 2021. The Author(s).
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Clin Microbiol. 2020 Sep 22;58(10):
pubmed: 32747400
Mol Cells. 2021 Jun 30;44(6):392-400
pubmed: 34059562
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Infect Genet Evol. 2021 Dec;96:105101
pubmed: 34624542
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Intern Med. 2021 Jun;174(6):811-821
pubmed: 33721517
Int J Environ Res Public Health. 2020 Jun 19;17(12):
pubmed: 32575505
J Infect. 2021 Sep;83(3):381-412
pubmed: 34058261
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541
J Infect. 2021 Oct 20;:
pubmed: 34687831
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
PLoS One. 2020 Oct 23;15(10):e0241165
pubmed: 33095811
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
BMJ Evid Based Med. 2021 Dec;26(6):279-284
pubmed: 32788164
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
PLoS One. 2021 Jun 29;16(6):e0253889
pubmed: 34185813
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
J Infect. 2020 Aug;81(2):e39-e45
pubmed: 32504735
Mil Med Res. 2021 Aug 31;8(1):47
pubmed: 34465396
N Engl J Med. 2020 Aug 6;383(6):e37
pubmed: 32501664
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Cell Host Microbe. 2021 Jul 14;29(7):1063-1075
pubmed: 34174992
Clin Chem Lab Med. 2020 Aug 26;58(12):2107-2111
pubmed: 32845861
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404